Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRC01 in severe refractory systemic lupus erythematosus
NCT07364396Phase 2Not yet recruiting
- Sponsor
- Curocell Inc.
- Start
- Feb 2026
- Primary completion
- Jun 2030
- Modality
- CAR-T Cells
01
Overview
A Phase 2 trial of anbalcabtagene autoleucel in systemic lupus erythematosus (SLE), lupus nephritis (LN), sponsored by Curocell Inc.. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
anbalcabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07364396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07364396.